Gan & Lee Pharmaceuticals Expects 2025 Profit to Jump Up to 95%

Gan & Lee Pharmaceuticals (603087.SH) Issues Positive Profit Alert, Forecasts 2025 Net Profit Attributable to Owners to Increase 78.96% to 95.23% YoY

Gan & Lee Pharmaceuticals (603087.SH): Insulin Glargine Injection and Its Pre-filled Pen Receive Drug Registration Approval in Ethiopia

Gan & Lee Pharmaceuticals Gets EU Approval for Insulin Injection; Shares Up 4%

Sandoz Receives European Commission Approval for Ondibta Insulin Glargine

Gan & Lee Pharmaceuticals Dismisses CFO and Vice President

Gan & Lee Pharmaceuticals Removes CFO, Appoints Acting CFO

INDIA STOCKS-Indian equity benchmarks eye muted start on persistent foreign outflows

Gan & Lee Pharmaceuticals Gets Clinical Trial Approval For Atopic Dermatitis Drug

Once-Monthly Glp-1 Ra | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (Gradual-3) of the First Chinese Once-Monthly Glp-1 Ra for Weight Management

Gan&Lee Pharmaceuticals: Business Operations Remain Normal

Gan&Lee Pharmaceuticals (603087.SH): CHMP Grants Positive Opinion for Marketing Authorization Application (MAA) of Insulin Glargine Injection (Ondibta®) in EU

BUZZ-China's Gan & Lee Pharma jumps most in 5 months on Biomm tie-up

3 Billion Yuan Deal! Gan & Lee Pharmaceuticals Hits Daily Limit, Drug ETF (562050) Surges Over 1%! Hong Kong Stock Connect Innovative Drug Leaders Gain Momentum, 520880 Premium Turns Positive

Gan & Lee Pharmaceuticals Says It Signed Supply Framework Agreement With Biomm Worth Expected at Least 3 Bln Yuan

BRIEF-Gan & Lee Pharmaceuticals Signs Framework Agreement